ClinicalTrials.gg
CompletedNCT06535399Updated Jan 23, 2026

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

A Phase 1 interventional study of BMS-986369 in Hepatic Impairment and Healthy Volunteers, sponsored by Celgene. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Diseases by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Liver Diseases · Bristol-Myers Squibb.

Started
2024
with 2 others
Phase 1
7 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Liver Diseases by Bristol-Myers Squibb, this one is one of 3 that started in 2024, is one of 7 in phase 1, and was the 11th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

None of the 11 studies in Liver Diseases by Bristol-Myers Squibb is open now. The open studies under Liver Diseases, anywhere →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Liver Diseases by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.

03

Conditions studied

  • Hepatic Impairment
  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Pharmacokinetics
  • Liver Diseases
  • Moderate and Severe Hepatic Impairment
  • BMS-986369
  • CC-99282
  • Hepatic Impairment
  • Golcadomide
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for all Participants (Group A, Group B, Group C):

  • (BMI) between 18 and 40 kg/m\^2 (inclusive), and body weight ≥ 50 kg.

Inclusion Criteria for Participants with Moderate or Severe Hepatic Impairment (Group A and Group B):

  • Participants have moderate HI (Group A), severe HI (Group B) or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
  • Participants have moderate (Group A) or severe (Group B) HI as defined by National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria.

Inclusion Criteria for a Matched Healthy Participant (Group C):

  • Participants must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions as agreed by the investigator and the Sponsor Medical Monitor.
  • Participants must be free of any disease that would interfere with the study evaluations.

Exclusion Criteria for all Participants (Group A, Group B, and Group C):

  • Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
  • History of major surgery within 8 weeks before the study intervention administration.
  • Any other clinically significant medical, psychiatric, and/or social reason, or other active issues, as determined by the investigator.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Group A: BMS-986369 Moderate Hepatic Impairment

    Drug: BMS-986369

  • Experimental
    Group B: BMS-986369 Severe Hepatic Impairment

    Drug: BMS-986369

  • Experimental
    Group C: BMS-986369 Normal Hepatic Function

    Drug: BMS-986369

Interventions

  • Specified dose on specified days

    Also known as: Golcadomide

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to approximately 44 days

  2. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to approximately 44 days

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to approximately 44 days

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to approximately 44 days

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to approximately 44 days

  3. Number of participants with physical examination abnormalities

    Time frame: Up to approximately 44 days

  4. Number of participants with vital sign abnormalities

    Time frame: Up to approximately 44 days

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to approximately 44 days

  6. Number of participants with clinical safety laboratory test abnormalities

    Time frame: Up to approximately 44 days

07

Study locations

3 sites
  • Local Institution - 0001
    Chandler, Arizona 85225, United States
  • Local Institution - 0002
    Orlando, Florida 32809, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Nov 2025, 14 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 14 months is close to that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Aug 15, 2024
Primary completionActual
Nov 12, 2025
CompletionActual
Nov 12, 2025
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535399
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Aug 15, 2024
Primary completion
Nov 12, 2025
Completion
Nov 12, 2025
Last update
Jan 23, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion